Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?

Gibson CM, Finks SW.

Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review.

PMID:
28390791
2.

Direct factor Xa inhibitor edoxaban: from bench to clinical practice.

Brekelmans M, Middeldorp S, Coppens M.

Expert Rev Hematol. 2015 Dec;8(6):707-25. doi: 10.1586/17474086.2015.1111756. Epub 2015 Nov 11. Review.

PMID:
26560872
3.

Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.

Kubli KA, Snead JA, Cheng-Lai A.

Cardiol Rev. 2016 Jul-Aug;24(4):205-10. doi: 10.1097/CRD.0000000000000104. Review.

PMID:
26991962
4.

Edoxaban, a Novel Oral Factor Xa Inhibitor.

Minor C, Tellor KB, Armbruster AL.

Ann Pharmacother. 2015 Jul;49(7):843-50. doi: 10.1177/1060028015579426. Epub 2015 Apr 8. Review.

PMID:
25855704
5.

Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Dzeshka MS, Lip GY.

Expert Opin Pharmacother. 2015;16(17):2661-78. doi: 10.1517/14656566.2015.1104301. Epub 2015 Nov 11. Review.

PMID:
26559069
6.

Italian intersociety consensus on DOAC use in internal medicine.

Prisco D, Ageno W, Becattini C, D'Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F; SIMI (Italian Society of Internal Medicine); FADOI (Federation of Associations of Hospital Doctors on Internal Medicine); SISET (Italian Society for the Study of Haemostasis and Thrombosis).

Intern Emerg Med. 2017 Apr;12(3):387-406. doi: 10.1007/s11739-017-1628-6. Epub 2017 Feb 13.

PMID:
28191610
7.

Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.

Shirley M, Dhillon S.

Drugs. 2015 Nov;75(17):2025-34. doi: 10.1007/s40265-015-0495-6. Review.

PMID:
26546477
8.

Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.

Barrios V, Escobar C.

Future Cardiol. 2016 Jul;12(4):419-33. doi: 10.2217/fca-2016-0021. Epub 2016 Apr 28. Review.

PMID:
27121025
9.

Establishing Edoxaban's Role in Anticoagulation.

Guirguis E, Brown D, Grace Y, Patel D, Henningfield S.

J Pharm Pract. 2016 Jun;29(3):228-38. doi: 10.1177/0897190016647314. Review.

PMID:
27169733
10.

Edoxaban: a review in nonvalvular atrial fibrillation.

McCormack PL.

Am J Cardiovasc Drugs. 2015 Oct;15(5):351-61. doi: 10.1007/s40256-015-0148-x. Review.

PMID:
26369340
11.

Risk impact of edoxaban in the management of stroke and venous thromboembolism.

Hurst KV, O'Callaghan JM, Handa A.

Vasc Health Risk Manag. 2016 Aug 11;12:329-35. doi: 10.2147/VHRM.S94679. eCollection 2016. Review.

12.

Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.

Barrios V, Escobar C.

Expert Rev Cardiovasc Ther. 2015;13(7):811-24. doi: 10.1586/14779072.2015.1053871. Epub 2015 Jun 11. Review.

PMID:
26068539
13.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.

Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042.

PMID:
20934556
14.

Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.

Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H.

Thromb Haemost. 2016 Sep 27;116(4):747-53. doi: 10.1160/TH16-03-0244. Epub 2016 Jul 21.

PMID:
27440518
15.

Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.

Preblick R, Kwong WJ, White RH, Goldhaber SZ.

Hosp Pract (1995). 2015;43(5):249-57. doi: 10.1080/21548331.2015.1099412. Epub 2015 Nov 7.

PMID:
26549305
16.

The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Minguet J, Sims HM, Smith KH, Bramlage P.

Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1.

PMID:
27817212
17.

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.

Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, Henderson DA, Mercuri MF, Rutman H, Antman EM, Braunwald E.

Am Heart J. 2016 Feb;172:144-51. doi: 10.1016/j.ahj.2015.11.004. Epub 2015 Dec 1.

PMID:
26856226
18.

Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.

Switzer MP, Wani P, Gosavi S, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2015;13(2):98-104. Review.

PMID:
26695421
19.

Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.

Dentali F, Fantoni C.

Intern Emerg Med. 2017 Aug;12(5):565-567. doi: 10.1007/s11739-017-1695-8. Epub 2017 Jun 27.

PMID:
28656545
20.

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.

Nakamura M, Yamada N, Ito M.

J Atheroscler Thromb. 2017 Jun 1;24(6):560-565. doi: 10.5551/jat.RV17005. Epub 2017 Apr 7. Review.

Supplemental Content

Support Center